

Sheet 1 of 9

| | | | |
|----------------------------------------|------------------------------------------------------------|----------------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002/ 4804B | Application No. 10/849,664 |
| | | Applicant Aladar Szalay et al. | |
| | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |

(37 CFR §1.98(b))

U.S. Patent Documents

| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
|------------------|-----------|-----------------|------------------|----------------------|-------|----------|----------------------------|
| ZUK | AA | 2003/0009015 | 01/09/03 | Ulrich et al. | 536 | 23.1 | 06/25/97 |
| | AB | 2003/0031681 | 02/13/03 | Mc Cart et al. | 424 | 186.1 | 11/13/01 |
| | AC | 2003/0086906 | 05/08/03 | Mastrangelo et al. | 424 | 93.2 | 11/04/02 |
| | AD | 2003/0165465 | 09/04/03 | Roberts et al. | 424 | 93.2 | 06/13/02 |
| | AE | 2003/0198627 | 10/23/03 | Arts et al. | 424 | 93.21 | 08/23/02 |
| | AF | 2003/0228330 | 12/11/03 | Falkner et al. | 424 | 232.1 | 03/14/03 |
| | AG | 4,722,848 | 02/02/88 | Paoletti et al. | 424 | 199.1 | 06/19/84 |
| | AH | 5,693,533 | 12/02/97 | Raney et al. | 435 | 366 | 12/07/94 |
| | AI | 5,718,902 | 02/17/98 | Yilma et al. | 424 | 211.1 | 06/17/91 |
| | AJ | 5,830,702 | 11/03/98 | Portnoy et al. | 435 | 69.3 | 12/30/94 |
| | AK | 6,093,700 | 07/25/00 | Mastrangelo et al. | 514 | 44 | 02/20/97 |
| | AL | 6,190,657 | 02/20/01 | Pawelek et al. | 424 | 93.1 | 06/04/96 |
| | AM | 6,428,968 | 08/06/02 | Molnar-Kimber et al. | 435 | 7.23 | 11/08/99 |
| | AN | 6,455,673 | 09/24/02 | Collier | 530 | 350 | 02/16/99 |
| | AO | 6,548,068 | 04/15/03 | Schlom et al. | 424 | 199.1 | 01/07/00 |
| | AP | 6,596,279 | 07/22/03 | Paoletti et al. | 424 | 199.1 | 08/14/98 |
| | AQ | 6,627,160 | 09/03/03 | Wold et al. | 424 | 93.2 | 09/19/01 |
| ZUK | AR | 6,685,935 | 02/03/04 | Pawelek et al. | 424 | 93.2 | 07/21/99 |

Foreign Patent Documents or Published Foreign Patent Applications

| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
|------------------|-----------|-----------------|------------------|--------------------------|-------|----------|-------------|----|
| | | | | | | | Yes | No |
| ZUK | AS | 0 037 441 | 10/14/81 | EP, A1 | | | | |
| | AT | 0 037 441 | 05/09/84 | EP, B1 | | | | |
| | AU | 03/045153 | 06/05/03 | PCT A1 | | | | |
| | AV | 03/102168 | 12/11/03 | PCT A1 | | | | |
| | AW | 1 281 777 | 02/05/03 | EP A1 | | | | |
| ZUK | AX | 99/32646 | 07/01/99 | PCT | | | | |

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| Examiner Signature <i>Robert A. Kelly</i> | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

OIP E

FEB 17 2005

Sheet 2 of 9

| | | | |
|---------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|----------------------------------------------|-------------------------------|
| Substitute Form PTO-449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002/ 4804B | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | Applicant Aladar Szalay et al. | |
| | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|-------------------------------------------------------------------------|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Examiner Initial | Desig. ID | Document |
| ZMK | AY | "Generation of Recombinant Vaccinia Viruses," Unit 16.17 in <i>Short Protocols in Molecular Biology 2nd edition: a compendium of Methods from Current Protocols in Molecular Biology</i> , Green Publishing and Wiley-Interscience Supplement 15:16.71-16.82 (1992) |
| | AZ | Adonai <i>et al.</i> , "Ex vivo cell labeling with ⁶⁴ Cu-pyruvaldehyde-bis(N ¹ -methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography," <i>Proc. Natl. Acad. Sci. USA</i> 99: 3030-3035 (2002) |
| | BA | Altschul <i>et al.</i> , "Basic local alignment search tool," <i>J Molec Biol</i> 215:403-410 (1990) |
| | BB | Ando, N. and M. Matumoto, "Unmasking of growth of dermovaccinia strain dairen I in L cells by acid treatment of cells after virus adsorption," <i>Japan. J. Microbiol.</i> 14(3): 181-186 (1979) |
| | BC | Antoine <i>et al.</i> , "The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses," <i>Virology</i> 244: 365-396 (1998) |
| | BD | ATCC Accession No. 59324 |
| | BE | ATCC Accession No. 59325 |
| | BF | ATCC Accession Nos. CCL-121 |
| | BG | ATCC Accession Nos. CRL-12011 |
| | BH | ATCC Accession Nos. CRL-12012 |
| | BI | ATCC catalog no. 700294 |
| | BJ | ATCC No. CCL-107 |
| | BK | ATCC No. CRL-6475 |
| | BL | ATCC under Accession number: VR-1549 |
| | BM | Barrett <i>et al.</i> , "Yellow Fever Vaccines," <i>Biologicals</i> 25:17-25 (1997) |
| | BN | Bauerschnitz <i>et al.</i> , "Treatment of Ovarian Cancer with a Tropism Modified Oncolytic Adenovirus," <i>Cancer Research</i> 62: 1266-1270 (2002) |
| | BO | Benes <i>et al.</i> , "M13 and pUC vectors with new unique restriction sites for cloning," <i>Gene</i> 130: 151-152 (1993) |
| | BP | Bernards <i>et al.</i> , "Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector," <i>Proc. Natl. Acad. Sci. USA</i> 84: 6854-6858 (1987) |
| | BQ | Beshara <i>et al.</i> , "Kinetic analysis of ⁵⁹ Fe-labelled iron(III) hydroxide-sucrose complex following blous administration using positron emission tomography," <i>Br. J. Haematol.</i> 104: 288-295 (1999) |
| | BR | Beshara <i>et al.</i> , "Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography," <i>Br. J. Haematol.</i> 104: 296-302 (1999) |
| | BS | Bisno <i>et al.</i> , "Streptococcal infections of skin and soft tissues," <i>N. Engl. J. Med.</i> 334(4): 240-245 (1996) |
| ZMK | BT | Blakemore, "Magnetotactic Bacteria," <i>Annu. Rev. Microbiol.</i> 36: 217-238 (1982) |

Examiner Signature

E. B. Kelly

Date Considered

6/2/06


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------------------------|--|-------------------------------|--|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/ 4804B | | Application No. 10/849,664 | |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Ajadar Szalay et al. | | | |
| | | | | Filing Date May 19, 2004 | | Group Art Unit 1632 1633 | |
| Other Documents (Include Author, Title, Date, and Place of Publication) | | | | | | | |
| Examiner Initial | Desig. ID | Document | | | | | |
| <i>RLK</i> | BU | Broder, C.C. and P.L. Earl, "Recombinant Vaccinia Viruses," Mol. Biotechnol. 13: 223-245 (1999) | | | | | |
| | BV | Brouqui, P. and D. Raoult, "Endocarditis due to rare and fastidious bacteria," Clinical Microbiology Reviews 14(1): 177-207 (2001) | | | | | |
| | BW | Calonder <i>et al.</i> , "Kinetic modeling of $^{55}\text{Fe}/^{55}\text{Mn}$ -Citrate at the Blood-Brain Barrier by Positron Emission Tomography," J. Neurochem. 73: 2047-2055 (1999) | | | | | |
| | BX | Carrillo and Lipman <i>et al.</i> , "The Multiple Sequence Alignment Problem in Biology," SIAM J Applied Math 48:1073-1082 (1988) | | | | | |
| | BY | Chakrabarti <i>et al.</i> , "Vaccinia virus expression vector: coexpression of β -galactosidase provides visual screening of recombinant virus plaques," Mol. Cell Biol. 5:3403-3409 (1985) | | | | | |
| | BZ | Chakrabarti <i>et al.</i> , "Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression," BioTechniques 23(6): 1094-1097 (1997) | | | | | |
| | CA | Chamberlain <i>et al.</i> , "Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines," Cancer Res. 56: 2832-2836 (1996) | | | | | |
| | CB | Child <i>et al.</i> , "Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence <i>in vivo</i> ," Virology 174:625-629 (1990) | | | | | |
| | CC | Colinas <i>et al.</i> , "A DNA ligase gene in the copenhagen strain of vaccinia virus is nonessential for viral replication and recombination," Virology 179: 267-275 (1990) | | | | | |
| | CD | Cusumano <i>et al.</i> , "Synergic activities of streptococcal pyrogenic exotoxin A and lipoteichoic acid in cytokine induction," Microbiologica 23(1): 37-45 (2000) | | | | | |
| | CE | Davison, A. J. and B. Moss, "Structure of Vaccinia Virus Early Promoters," J. Mol. Biol. 210: 749-769 (1989) | | | | | |
| | CF | Davison <i>et al.</i> , "New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins," Nucleic Acids Research 18: 4285-4286 (1990) | | | | | |
| | CG | Devereux, J., <i>et al.</i> , "A comprehensive set of sequence analysis programs for the VAX," Nucleic Acids Research 12(1): 387-95 (1984) | | | | | |
| | CH | Earl <i>et al.</i> , "T-Lymphocyte Priming and Protection Against Friend Leukemia by Vaccinia-Retrovirus <i>env</i> Gene Recombinant," Science 234: 728-731 (1986) | | | | | |
| | CI | Ebert <i>et al.</i> , "Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats," Cancer Research 63: 3605-3611 (2003) | | | | | |
| | CJ | Ebert <i>et al.</i> , "Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer," Cancer Research 64: 3265-3270 (2004) | | | | | |
| | CK | Estin <i>et al.</i> , "Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy," Proc. Natl. Acad. Sci. USA 85: 1052-1056 (1988) | | | | | |
| | CL | Ferretti <i>et al.</i> , "Complete genome sequence of an M1 strain of <i>Streptococcus pyogenes</i> ," Proc. Natl. Acad. Sci. USA 98(8): 4658-4663 (2001) | | | | | |
| | CM | Flexner <i>et al.</i> , "Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen," Nature 355:259-262 (1988) | | | | | |
| | CN | Flexner <i>et al.</i> , "Characterization of Human Immunodeficiency Virus <i>gag/pol</i> Gene Products Expressed by Recombinant Vaccinia Viruses," Virology 166: 339-349 (1988) | | | | | |
| | CO | Giedlin <i>et al.</i> , "Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from <i>Field's Virology</i> ?" Cancer Cell 4: 241-243 (2003) | | | | | |
| <i>RLK</i> | CP | Goebel <i>et al.</i> , "The complete DNA sequence of vaccinia virus," Virology 179:247-266 (1990) | | | | | |
| Examiner Signature <i>Rand J. Kelly</i> | | | | Date Considered 6/2/06 | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 608; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |


| | | | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------------------------|--|-------------------------------|--|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/ 4804B | | Application No. 10/849,664 | |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Aladar Szalay et al. | | | |
| | | | | Filing Date May 19, 2004 | | Group Art Unit 1632 1633 | |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | | | |
| Examiner Initial | Desig. ID | Document | | | | | |
| ZUK | CQ | Goebel et al., "Appendix to 'The complete DNA Sequence of Vaccinia Virus,'" Virology 179: 517-563 (1990) | | | | | |
| | CR | Green et al., "Necrotizing Fasciitis," Chest 110(1):219-229 (1996) | | | | | |
| | CS | Greinwald et al., "Treatment of lymphangiomas in children: an update of Picibanil (Ok-432) sclerotherapy," Otolaryngol Head Neck Surg 121(4): 381-387 (1999) | | | | | |
| | CT | Gribskov et al., "Sigma factors from E. coli, B. subtilis, phage SP01, and phage T4 are homologous proteins," Nucl. Acids Res. 14:6745-6763 (1986) | | | | | |
| | CU | Huang et al., "Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice," Mol. Ther. 8(3): 434-440 (2003) | | | | | |
| | CV | Hurst et al., "A novel model of a metastatic human breast tumour xenograft line," Br. J. Cancer 68: 274-276 (1993) | | | | | |
| | CW | Isaacs et al., "Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence," Proc Natl Acad Sci U S A. 89:628-632 (1992) | | | | | |
| | CX | Johnson et al., "An update on the vaccinia virus genome," Virology 196: 381-401 (1993) | | | | | |
| | CY | Kantor et al., "Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine," J. Natl. Cancer Inst. 84: 1084-1091 (1992) | | | | | |
| | CZ | Katz et al., "Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein," J. Virology 77:12266-12275 (2003) | | | | | |
| | DA | Kotwal et al., "Mapping and Insertional Mutagenesis of a Vaccinia Virus Gene Encoding a 13, 800-Da Secreted Protein," Virology 171:579-587 (1989) | | | | | |
| | DB | Kozak, M., "Structural features in Eukaryotic mRNAs that modulate the Initiation of Translation," J. Biol. Chem. 266:19867-19870 (1991) | | | | | |
| | DC | Lamberton et al., "Construction and characterization of a bioluminescent Streptococcus pyogenes," Proceedings of the 12th International Symposium on Bioluminescence and Chemiluminescence" Progress & Current Applications, Stanley, P.E. and L.J. Kricka et al-(Eds). World Scientific Publishing Co. Pte. Ltd., pp 85-88 (2002) | | | | | |
| | DD | Lamberton et al., "Generation and characterization of a bioluminescent Streptococcus pyogenes," Proceedings of the 12th International Symposium on Bioluminescence & Chemiluminescence: 5-9 April 2002, Robinson College, University of Cambridge, UK, p 3.22 (2002) | | | | | |
| | DE | Lathe et al., "Tumour prevention and rejection with recombinant vaccinia," Nature (London) 326: 878-880 (1987) | | | | | |
| | DF | Lee et al. "Prodrug and antedrug: two diametrical approaches in designing safer drugs," Arch. Pharm. Res. 25(2): 111-136 (2002) | | | | | |
| | DG | Lee et al., "Molecular attenuation of vaccinia virus: mutant generation and animal characterization," Journal of Virology 66:2617-2630 (1992) | | | | | |
| ✓ | DH | Leenders et al., "Blood to brain iron uptake in one Rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol," J. Neural Transm. Suppl. 43: 123-132 (1994) | | | | | |
| ZUK | DI | Lemmon et al., "Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment," Gene Therapy 4: 791-796 (1997) | | | | | |
| Examiner Signature <i>R. J. Kelly</i> | | | | Date Considered 6/2/06 | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

| | | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|----------------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/ 4804B | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Aladar Szalay et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| <i>mk</i> | DJ | Lemmon et al., "Anaerobic bacteria as a gene delivery system to tumors," Proceedings of the 85th Annual Meeting of the American Association for Cancer Research, San Francisco, CA April 10-13, 1994, published in: Proc. Am. Cancer Research Assn 35: 374 (1994) | | | |
| | DK | Lewis et al., "Comparison of Four ⁶⁴ Cu-Labeled Somatostatin Analogues in Vitro and in a Tumor-Bearing Rat Model: Evaluation of New Derivatives for Positron Emission Tomography Imaging and Targeted Radiotherapy," J. Med. Chem. 42: 1341-1347 (1999) | | | |
| | DL | Li et al., "Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective Inhibitor of angiogenesis and hypoxic tumor growth," Cancer Gene Therapy 10: 105-111 (2003) | | | |
| | DM | Liau et al., "Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens," J. Neurosurg. 90(6): 1115-1124 (1999) | | | |
| | DN | Liu et al., "An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency," Molecular Therapy 9(6): 786-803 (2004) | | | |
| | DO | Lopez et al., "Infections in children with malignant disease in Argentina," Cancer 47(5): 1023-1030 (1981) | | | |
| | DP | Mayford et al., "CaMKII Regulates the Frequency-Response Function of Hippocampal Synapses for the Production of Both LTD and LTP," Cell 81: 891-904 (1995) | | | |
| | DQ | Mayr et al., "The Smallpox Vaccination Strain MVA: Marker, Genetic Structure, Experience Gained with the Parenteral Vaccination and Behavior in Organisms with a Debilitated Defense Mechanism," Zentbl. Bakteriell. Hyg. Abt. I Orig. B 167: 375-390 (1978) [In German, English abstract on first page of article] | | | |
| | DR | McAllister et al., "Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases," J. Virol. 74:9197-9205 (2000). | | | |
| | DS | McAneny et al., "Results of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer," Ann. Surg. Oncol. 3(5): 495-500 (1996) | | | |
| | DT | Mikryukov et al., "Structural-functional organization of segment of vaccinia virus genome," Soviet Biotechnology (Biokhimiya) 4: 19-25 (1988) [corresponds to pages 442-449 in the Russian language edition] | | | |
| | DU | Moore et al., "Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor," EMBO J. 1992 11:1973-1980, corrigendum in The EMBO Journal 11(9): 3490 (1992) | | | |
| | DV | Moss, B., "Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety," Proc. Natl. Acad. Sci. USA 93: 11341-11348 (1996) | | | |
| | DW | Moss, B., "Poxvirus vectors: cytoplasmic expression of transferred genes," Curr. Opin. Genet. Dev. 3: 86-90 (1993) | | | |
| | DX | Mullen et al., "Viral Oncolysis," The Oncologist 7: 106-119 (2002) | | | |
| | DY | Mulryan et al., "Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors," Mol Cancer Ther 1(12): 1129-1137 (2002) | | | |
| <i>mk</i> | DZ | Munagala et al., "The purine nucleoside phosphorylase from <i>Trichomonas vaginalis</i> is a homologue of the bacterial enzyme," Biochemistry 41(33): 10382-10389 (2002) | | | |
| Examiner Signature <i>Robert Kelly</i> | | | Date Considered 6/2/06 + 6/19/06 | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | | | | | | |
|---------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------------------------|--|-------------------------------|--|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/ 4804B | | Application No. 10/849,664 | |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Aladar Szalay et al. | | | |
| | | | | Filing Date May 19, 2004 | | Group Art Unit 1632 1633 | |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | | | |
| Examiner Initial | Desig. ID | Document | | | | | |
| ZUK | EA | NCBI Protein AAA48282 | | | | | |
| | EB | NCBI Nucleotide AF012825 | | | | | |
| | EC | NCBI Nucleotide. AF095689 | | | | | |
| | ED | NCBI Nucleotide AF380138 | | | | | |
| | EE | NCBI Nucleotide AX003206 | | | | | |
| | EF | NCBI Nucleotide. AY009089 | | | | | |
| | EG | NCBI Nucleotide AY243312 | | | | | |
| | EH | NCBI Nucleotide AY484669 | | | | | |
| | EI | NCBI Nucleotide AY603355 | | | | | |
| | EJ | NCBI Nucleotide M35027 | | | | | |
| | EK | NCBI Nucleotide M57977 | | | | | |
| | EL | NCBI Nucleotide U94848 | | | | | |
| | EM | NCBI Nucleotide X69198 | | | | | |
| | EN | NCBI Nucleotide X94355 | | | | | |
| | EO | Needleman <i>et al.</i> , "A general method applicable to the search for similarities in the amino acid sequences of two proteins," J. Mol. Biol. 48:443-453 (1970) | | | | | |
| | EP | Nogrady, T., <i>Medicinal Chemistry A Biochemical Approach</i> , New York: Oxford University Press, pages 388-392 (1985) | | | | | |
| | EQ | Oertli <i>et al.</i> , "Non-replicating recombinant vaccinia virus encoding murine B-7 molecules effective costimulation of naive CD4 ⁺ splenocytes <i>in vitro</i> ," J. Gen. Virol. 77: 3121-3125 (1996) | | | | | |
| | ER | Okamoto <i>et al.</i> , "Severe impairment of anti-cancer effect of lipoteichoic acid-related molecule isolated from a penicillin-killed <i>Streptococcus pyogenes</i> in toll-like receptor 4-deficient mice," International Immunopharmacology 1(9-10): 1789-1795 (2001) | | | | | |
| | ES | Patel <i>et al.</i> , "A poxvirus-derived vector that directs high levels of expression of cloned genes in mammalian cells," Proc. Natl. Acad. Sci. USA 85: 9431-9435 (1988) | | | | | |
| | ET | Pawelek <i>et al.</i> , "Tumor-targeted <i>Salmonella</i> as a Novel Anticancer Vector," Cancer Therapy 57: 4537-4544 (1997) | | | | | |
| EU | Pearson <i>et al.</i> , "Improved tools for biological sequence comparison," Proc. Natl. Acad. Sci. USA 85:2444-2448 (1988) | | | | | | |
| EV | Pilcher, H., "GM Bug activates cancer drug: Bacteria targets medicine to shrivel mouse tumours," news @ nature.com, Published online: 22 April 2004; http://www.nature.com/news/2004/040419/full/040419-9.html , (accessed on November 18, 2004) | | | | | | |
| ZUK | EW | Pinkert <i>et al.</i> , "An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice," Genes & Dev. 1: 268-76 (1987) | | | | | |

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |


| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002/ 4804B | Application No. 10/849,664 |
|---------------------------------------------------------------------------------------------------------------|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|----------------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | Applicant Aladar Szalay et al. | |
| | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | |
| Examiner Initial | Desig. ID | Document | | |
| JK | EX | Plucienniczak et al., "Nucleotide sequence of a cluster and late genes in a conserved segment of the vaccinia virus genome," Nucleic Acids Research 13(3): 993-998 (1985) | | |
| | EY | Puhlmann et al., "Vaccinia virus as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant," Cancer Gene Therapy 7(1): 66-73 (2000) | | |
| | EZ | Qin, H. and S.K. Chatterjee, "Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF," Human Gene Ther. 7: 1853-1860 (1996) | | |
| | FA | Rao et al., "IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines," J. Immunol. 156: 3357-3365 (1996) | | |
| | PB | Rodriguez et al., "Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses," Proc. Natl. Acad. Sci. USA 86: 1287-1291 (1989) | | |
| | FC | Rolston et al., "In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients in cancer," Antimicrob. Agents Chemother. 34(11):2137-2141 (1990) | | |
| | FD | Roseman et al., "The vaccinia virus HindIII fragment: nucleotide sequence of the left 6.2kb," Virology 178: 410-418 (1990) | | |
| | FE | Roth et al., "p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge," Proc. Natl. Acad. Sci. USA 93: 4781-4786 (1996) | | |
| | FF | Schwartz and Dayhoff, eds., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, National Biomedical Research Foundation, pp. 353-358 (1979) | | |
| | FG | Shilo, B. and R.A. Weinberg, "DNA sequences homologous to vertebrate oncogenes are conserved in Drosophila melanogaster," Proc. Natl. Acad. Sci. USA 78:6789-6792 (1981) | | |
| | FH | Shinozaki et al., "Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus," Mol. Ther. 9(3): 368-376 (2004) | | |
| | FI | Silva et al., "Cloning, overexpression, and purification of functional human purine nucleoside phosphorylase," Protein Expr. Purif. 27(1): 158-164 (2003) | | |
| | FJ | Smith, T.F. and M.S. Waterman, "Comparison of biosequences," Adv. Appl. Math. 2:482-489 (1981) | | |
| | FK | Sorscher et al., "Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines," Gene Therapy 1(4): 233-238 (1994) | | |
| | FL | Stevens, D.L., "Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment," Emerg. Infect. Dis. 1(3): 69-78 (1995) | | |
| | FM | Sugimoto, M. and K. Yamanouchi, "Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines," Vaccine 12(8): 675-681 (1994) | | |
| | FN | Sugimoto et al., "Gene structures of low-neurovirulent vaccinia virus LC16m0, LC16m8, and their Lister Original (LO) strains," Microbial. Immunol. 29: 421-428 (1985) | | |
| | FO | Suvorov et al., "Physical and genetic chromosomal map of an M type 1 strain of Streptococcus pyogenes," J. Bacteriol. 178(18): 5546-5549 (1996) | | |
| | FP | Suzuki et al., "Management of orbital lymphangioma using intralesional injection of OK-432," Br. J. Ophthalmol. 84(6): 614-617 (2000) | | |
| JK | FQ | Sze et al., "Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival," J. Vasc. Interv. Radiol. 14(3): 279-290 (2003) | | |

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | | | | | |
|---------------------------------------------------------------------------------------------------------------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------------------------|--|-------------------------------|--|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/ 4804B | | Application No. 10/849,664 | |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Aladar Szalay et al. | | | |
| | | | | Filing Date May 19, 2004 | | Group Art Unit 1632-1633 | |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | | | |
| Examiner Initial | Desig. ID | Document | | | | | |
| <i>PK</i> | FR | Takahashi-Nishimaki <i>et al.</i> , "Genetic analysis of vaccinia virus Lister strain and its attenuated mutant LC16m8: production of intermediate variants by homologous recombination," J. Gen. Virol. 68: 2705-2710 (1987) | | | | | |
| <i>PK</i> | FS | Theys <i>et al.</i> , "Tumor-specific gene delivery using genetically engineered bacteria," Curr Gene Ther 3(3): 207-221 (2003) | | | | | |
| | ET | Timiryasova <i>et al.</i>, "[Analysis of reporter gene expression at different segments of the vaccinia virus genome]," Mol. Biol. (Mosk.) 27(2): 392-401 (1993) [article in Russian, English abstract on last page of article] | | | | | |
| <i>PK</i> | FU | Timiryasova <i>et al.</i> , "Construction of recombinant vaccinia viruses using PUV-inactivated virus as a helper," BioTechniques 31: 534-540 (2001) | | | | | |
| | FV | Toth <i>et al.</i> , "An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated <i>Wnt</i> signaling," Cancer Research 64: 3638-3644 (2004) | | | | | |
| | FW | Tsung <i>et al.</i> , "Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light," J. Virol. 70: 165-171 (1996) | | | | | |
| | FX | Umphress <i>et al.</i> , "Vaccinia virus mediated expression of human APC induces apoptosis in colon cancer cells," Transgenics 4:19-33 (2003) | | | | | |
| | FY | Veijola <i>et al.</i> , "Cloning, Baculovirus Expression, and Characterization of the α Subunit of Prolyl 4-Hydroxylase from the nematode <i>Caenorhabditis elegans</i> ," J. Biol. Chem. 269: 26746-26753 (1994) | | | | | |
| | FZ | Vidal <i>et al.</i> , "Tissue-specific control elements of the Thy-1 gene," EMBO J. 9(3): 833-840 (1990) | | | | | |
| | GA | Watson <i>et al.</i> Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin/Cummings Pub. co., p.224 | | | | | |
| | GB | Wolffe <i>et al.</i> , "Deletion of the vaccinia virus BSR gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination," Journal of Virology 67(8): 4732-4741 (1993) and erratum in Journal of Virology, vol. 67, pp5709-5711 (1993) | | | | | |
| | GC | Wu <i>et al.</i> , "High resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment," PNAS USA 97(15): 8495-8500 (2000) | | | | | |
| | GD | Yang <i>et al.</i> , "Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases," Proc. Natl. Acad. Sci. USA 97(3):1206-1211 (2000) | | | | | |
| | GE | Yang <i>et al.</i> , "Effects of growth medium composition, iron sources and atmospheric oxygen concentrations on production of luciferase-bacterial magnetic particle complex by a recombinant <i>Magnetospirillum magneticum</i> AMB-1," Enzyme Microb. Technol. 29: 13-19 (2001) | | | | | |
| | GF | Yazawa <i>et al.</i> , "Current progress in suicide gene therapy for cancer," World J. Surg 26(7): 783-789 (2002) | | | | | |
| | GG | Yoshida <i>et al.</i> , "Cell growth-inhibitory action of SAGP, an antitumor glycoprotein from <i>Streptococcus pyogenes</i> (Su strain)," Jpn. J. Pharmacol. 45(2): 143-147 (1987) | | | | | |
| | GH | Yoshida <i>et al.</i> , "Characterization of a streptococcal antitumor glycoprotein (SAGP)," Life Sciences 62(12): 1043-1053 (1998) | | | | | |
| <i>PK</i> | GI | Yoshida <i>et al.</i> , "Growth-inhibitory effect of streptococcal antitumor glycoprotein on human epidermoid carcinoma A431 cells: involvement of dephosphorylation of epidermal growth factor receptor," Cancer Research 61(16): 6151-6157 (2001) | | | | | |

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| Examiner Signature <i>R. A. Kelly</i> | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §909; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | | | | | |
|---------------------------------------------------------------------------------------------------------------|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------------------------|--|----------------------------------------|--|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/ 4804B | | Application No. 10/849,664 | |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Aladar Szalay et al. | | | |
| | | | | Filing Date May 19, 2004 | | Group Art Unit 1632 1633 | |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | | | |
| Examiner Initial | Desig. ID | Document | | | | | |
| JK | GJ | Zimmermann <i>et al.</i> , "Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells," <i>Neuron</i> 12: 11-24 (1994) | | | | | |
| JK | GK | Zolotukhin <i>et al.</i> , "A "Humanized" Green Fluorescent Protein cDNA adapted for high-level expression in mammalian cells," <i>J. Virol.</i> 70:4646-4654 (1996) | | | | | |

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |